■ Details :

Following its successful bid in the Hebei Province volume-based procurement in December 2024, the contrast agent product Gadopentetate Dimeglumine Injection, which InnoPharmax has licensed to Shandong New Time Pharmaceutical, has also won the bid in the June centralized procurement organized by a 26-province alliance in China. This is expected to generate an annual demand of over 5 tons of the active pharmaceutical ingredient (API). Currently, this product ranks first among gadolinium-based contrast agents in China in terms of sales volume.

News report: https://www.sohu.com/a/908668434_121123913

According to the IQVIA database, the estimated demand for gadopentetate dimeglumine API in China is approximately 45 tons.

The Company serves as the exclusive agent in China for the gadopentetate dimeglumine API supplied by Qixing. It also obtained API marketing approval from the China National Medical Products Administration (NMPA) on July 5, 2024. This API is exclusively supplied for the production of Gadopentetate Dimeglumine Injection by Shandong New Time Pharmaceutical Co., Ltd.

In China, Gadopentetate Dimeglumine Injection will be commercially manufactured and marketed by Shandong New Time Pharmaceutical Co., Ltd., while the Company will act as the exclusive supplier of the API required for its commercial production.